EDRH
SRPT icon

Edmond de Rothschild Holding’s Sarepta Therapeutics SRPT Stock Holding History

Edmond de Rothschild Holding’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-86,510
Closed -$7.79M – 849
2021
Q4 		$7.79M Sell
86,510
-20,450
-19% -$1.75M 0.17% 132
2021
Q3 		$9.89M Buy
106,960
+32,600
+44% +$2.51M 0.23% 112
2021
Q2 		$5.78M Buy
+74,360
New +$5.64M 0.13% 154

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Edmond de Rothschild Holding's SRPT Position: Q1 2022 in Review

Edmond de Rothschild Holding sold out of Sarepta Therapeutics (SRPT) in Q1 2022, closing a stake of 86,510 shares — an estimated $7.79M sold.

Edmond de Rothschild Holding first reported a position in SRPT in Q2 2021 and held it in 3 quarters. The position peaked at $9.89M in Q3 2021. 328 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.

  • Edmond de Rothschild Holding reported no remaining Sarepta Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Edmond de Rothschild Holding sold 86,510 Sarepta Therapeutics shares in Q1 2022, an estimated $7.79M.
  • Edmond de Rothschild Holding first reported a position in Sarepta Therapeutics in Q2 2021 and held it in 3 quarters.
  • Edmond de Rothschild Holding's Sarepta Therapeutics position peaked at $9.89M in Q3 2021.
  • 328 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.

Based on Edmond de Rothschild Holding's 13F filing for Q1 2022, filed 10 May 2022.